MCID: PRP021
MIFTS: 53

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 15
Peripheral Nervous System Neoplasms 44 73
Nerve Sheath Neoplasm 12 76
Nerve Sheath Tumors 12 73
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 44
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 50 C3321 C4972

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to autonomic nervous system neoplasm and malignant cardiac peripheral nerve sheath neoplasm, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include the peripheral nervous system, brain and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up... more...

Related Diseases for Peripheral Nervous System Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 29.0 AKT1 ALK BACE1 CASP3 CNTN6 ENO2
2 malignant cardiac peripheral nerve sheath neoplasm 12.1
3 malignant triton tumor 11.1
4 parameningeal embryonal rhabdomyosarcoma 11.1 ALK TP53
5 gliofibroma 11.1 NF1 TP53
6 optic nerve neoplasm 11.0 ENO2 NF1 TP53
7 adult medulloblastoma 11.0 ENO2 MYCN TP53
8 cerebral neuroblastoma 11.0 ENO2 NGF TP53
9 juvenile pilocytic astrocytoma 11.0 ENO2 NF1 TP53
10 rare adenocarcinoma of the breast 11.0 AKT1 TP53
11 neuropathy, hereditary sensory and autonomic, type v 11.0 NGF NTRK1
12 meningeal melanomatosis 11.0 ENO2 NGF TP53
13 optic nerve glioma 11.0 ENO2 NF1 TP53
14 prolactin producing pituitary tumor 11.0 NGF NTRK1 TP53
15 bone ewing's sarcoma 11.0 ENO2 MYC MYCN
16 traumatic brain injury 10.9 CASP3 ENO2 NGF
17 cellular neurofibroma 10.9 CD34 TP53
18 ovary sarcoma 10.9 CD34 MYC
19 plexiform schwannoma 10.9 CD34 ENO2 NF1
20 adrenal neuroblastoma 10.9 ENO2 MYCN
21 ovarian angiosarcoma 10.9 CD34 MYC
22 infratentorial cancer 10.9 MYC MYCN TP53
23 intravascular fasciitis 10.9 ALK CD34
24 short-rib thoracic dysplasia 4 with or without polydactyly 10.9 CASP3 TP53
25 neuroma 10.9 ENO2 NF1 NGF
26 liver angiosarcoma 10.9 CD34 ENO2 TP53
27 primary effusion lymphoma 10.9 AKT1 CASP3 MYC
28 integumentary system cancer 10.9 AKT1 ENO2 TP53
29 ganglioneuroma 10.8 ENO2 MYCN NTRK1 NTRK2
30 cellular schwannoma 10.8 CD34 NF1 TP53
31 pharynx cancer 10.8 AKT1 CASP3 TP53
32 clear cell ependymoma 10.8 CD34 ENO2 TP53
33 lung meningioma 10.8 CD34 ENO2
34 hereditary sensory neuropathy 10.8 NGF NTRK1 NTRK2
35 intraneural perineurioma 10.8 ALK CD34 NF1
36 cerebral primitive neuroectodermal tumor 10.8 ENO2 MYC MYCN TP53
37 medullomyoblastoma 10.8 ENO2 MYC MYCN TP53
38 nodular ganglioneuroblastoma 10.8 ALK ENO2 MYCN NTRK2
39 muscle cancer 10.8 CD34 ENO2 TP53
40 deafness, autosomal recessive 74 10.8 BACE1 CASP3
41 peripheral nervous system disease 10.8 MFRP NGF PHOX2B
42 meninges sarcoma 10.8 CD34 TP53
43 rhabdomyosarcoma 2 10.8 ALK ENO2 MYCN TH
44 differentiated thyroid carcinoma 10.8 ALK NTRK1 TP53
45 organ system benign neoplasm 10.8 CD34 ENO2 NF1 TP53
46 status epilepticus 10.8 CASP3 ENO2 NTRK2
47 endocrine gland cancer 10.7 AKT1 ENO2 TP53
48 neonatal hypoxic and ischemic brain injury 10.7 ENO2 TH
49 central nervous system disease 10.7 BACE1 CASP3 NGF TH
50 male reproductive organ cancer 10.7 AKT1 CASP3 MYC TP53

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

GenomeRNAi Phenotypes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.6 ALK MYC NF1 NTRK2 AKT1
2 Decreased viability GR00221-A-2 9.6 NF1 NTRK2 AKT1
3 Decreased viability GR00221-A-3 9.6 MYC AKT1
4 Decreased viability GR00221-A-4 9.6 ALK NF1 NTRK2 AKT1
5 Decreased viability GR00402-S-2 9.6 ALK MYC NF1 NTRK2 AKT1

MGI Mouse Phenotypes related to Peripheral Nervous System Neoplasm:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 CASP3 ALK BACE1 AKT1 NFIC NGF
2 growth/size/body region MP:0005378 10.46 CASP3 ALK BACE1 AKT1 NTRK2 NFIC
3 cellular MP:0005384 10.39 AKT1 CASP3 CD34 BACE1 NTRK2 NUMBL
4 nervous system MP:0003631 10.39 CASP3 ALK BACE1 AKT1 NGF NUMBL
5 mortality/aging MP:0010768 10.37 AKT1 CASP3 ALK BACE1 NFIC NTRK2
6 homeostasis/metabolism MP:0005376 10.35 BACE1 AKT1 CASP3 ALK CD34 NTRK2
7 integument MP:0010771 10.26 AKT1 CASP3 ALK CD34 BACE1 NGF
8 normal MP:0002873 10.15 BACE1 AKT1 NTRK2 NGF NUMBL NTRK1
9 muscle MP:0005369 10.13 BACE1 AKT1 CASP3 NGF NTRK1 TP53
10 craniofacial MP:0005382 10.11 CASP3 NFIC NF1 TP53 ENO2 MYCN
11 hearing/vestibular/ear MP:0005377 10.09 CASP3 NTRK2 NUMBL NTRK1 TP53 MYC
12 liver/biliary system MP:0005370 10.05 AKT1 NTRK2 NF1 TP53 TH MYCN
13 no phenotypic analysis MP:0003012 10.01 BACE1 CASP3 NGF NTRK1 TH TP53
14 neoplasm MP:0002006 10 AKT1 ALK CD34 NF1 TH TP53
15 reproductive system MP:0005389 9.91 AKT1 CASP3 ALK NFIC NTRK2 NUMBL
16 pigmentation MP:0001186 9.87 CASP3 ALK NTRK1 TP53 MFRP MYC
17 respiratory system MP:0005388 9.85 CASP3 ALK AKT1 NTRK2 TH TP53
18 skeleton MP:0005390 9.61 AKT1 CASP3 ALK NFIC NTRK2 NF1
19 vision/eye MP:0005391 9.36 CASP3 ALK NTRK2 NGF NTRK1 TH

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Central Nervous System Stimulants Phase 4,Not Applicable
5 Dopamine Agents Phase 4,Not Applicable
6 Dopamine Uptake Inhibitors Phase 4
7 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Neurotransmitter Uptake Inhibitors Phase 4
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Gentamicins Phase 4,Not Applicable
11
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
14
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
15
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
16
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
17
Chlorhexidine Approved, Vet_approved Phase 2, Phase 3 55-56-1 9552079 2713
18
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
19
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
20
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
21 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
23 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
25
Isophosphamide mustard Phase 3,Phase 2 0
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Anticonvulsants Phase 2, Phase 3,Phase 1
28 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
29 calcium channel blockers Phase 2, Phase 3
30 Calcium, Dietary Phase 2, Phase 3
31 Chlorhexidine gluconate Phase 2, Phase 3
32 Diuretics, Potassium Sparing Phase 2, Phase 3
33 Excitatory Amino Acid Antagonists Phase 2, Phase 3
34 Excitatory Amino Acids Phase 2, Phase 3
35 Sodium Channel Blockers Phase 2, Phase 3
36
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
37
Peginterferon alfa-2b Approved Phase 2,Phase 1 99210-65-8, 215647-85-1
38
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
39
Diclofenac Approved, Vet_approved Phase 2 15307-86-5 3033
40
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
41
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
42
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
43
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
44
Lovastatin Approved, Investigational Phase 2,Phase 1 75330-75-5 53232
45
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
46
Pirfenidone Approved, Investigational Phase 2,Phase 1 53179-13-8 40632
47
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
48
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
49
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
50
Romidepsin Approved, Investigational Phase 2,Phase 1 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 230)
# Name Status NCT ID Phase Drugs
1 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
2 Dexmedetomidine and Propofol for Pediatric MRI Sedation Recruiting NCT03513757 Phase 4 propofol;Dexmedetomidine
3 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
4 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
5 First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Unknown status NCT00921037 Phase 2, Phase 3
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Recruiting NCT02471339 Phase 3
9 Effect of Lamotrigine on Cognition in NF1 Recruiting NCT02256124 Phase 2, Phase 3 Lamotrigine;Placebo
10 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
15 Medical Treatment of "High-Risk" Neurofibromas Unknown status NCT00846430 Phase 2 Peg-Interferon alpha-2b;Celecoxib (Celebrex);Temozolomide (temodar);Vincristine Sulfate (Oncovin)
16 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Completed NCT03090971 Phase 2 Diclofenac Sodium;Saline Solution
17 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Completed NCT02332902 Phase 2 Everolimus
18 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
19 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Completed NCT01673009 Phase 2 Gleevec
20 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
21 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
22 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
23 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
24 Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Completed NCT01412892 Phase 2 RAD001: Everolimus
25 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
26 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
27 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Completed NCT01140360 Phase 1, Phase 2 Gleevec
28 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
29 Study of PEG-Intron for Plexiform Neurofibromas Completed NCT00396019 Phase 2 PEG-Intron
30 A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Completed NCT00853580 Phase 2 Lovastatin ™
31 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
32 Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Completed NCT00754780 Phase 2 Pirfenidone
33 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
34 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed NCT00634270 Phase 2 Sirolimus
35 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
36 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
37 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
38 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
39 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
40 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
41 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Completed NCT00076102 Phase 2 Pirfenidone
42 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
43 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
44 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Completed NCT00030264 Phase 2 Methotrexate;Vinblastine
45 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Completed NCT00021541 Phase 2 tipifarnib
47 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
48 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
49 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Recruiting NCT03231306 Phase 2 Binimetinib
50 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Peripheral Nervous System Neoplasm:

19
The Peripheral Nervous System

MalaCards organs/tissues related to Peripheral Nervous System Neoplasm:

41
Brain, Bone, T Cells, Spinal Cord, Skin

Publications for Peripheral Nervous System Neoplasm

Articles related to Peripheral Nervous System Neoplasm:

# Title Authors Year
1
Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. ( 18480004 )
2008
2
Perineurioma: a distinctive and underrecognized peripheral nerve sheath neoplasm. ( 17425397 )
2007
3
Perineurioma of the finger: case report of a rare peripheral nerve sheath neoplasm of pure perineurial cell lineage. ( 9556280 )
1998
4
Human peripheral nerve sheath neoplasm: expression of Schwann cell-related markers and their relation to malignant transformation. ( 1656253 )
1991

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 AKT1 CASP3 MYC NGF NTRK1 NTRK2
2 12.81 AKT1 ALK CASP3 MYC NTRK1 TP53
3
Show member pathways
12.8 AKT1 CASP3 MYC NTRK1 TP53
4
Show member pathways
12.78 AKT1 CASP3 MYC NGF NTRK1 TP53
5
Show member pathways
12.69 AKT1 NF1 NGF NTRK1 NTRK2
6
Show member pathways
12.67 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
7
Show member pathways
12.4 AKT1 CASP3 NTRK1 NTRK2 TP53
8 12.25 AKT1 CASP3 MYC TP53
9 12.23 AKT1 CASP3 MYC NF1 NGF NTRK1
10 12.2 MYC MYCN NTRK1 TP53
11 12.15 AKT1 CASP3 MYC TP53
12 12.12 CASP3 NGF NTRK2 PHOX2B TH
13 12.08 AKT1 CASP3 MYC NF1 TP53
14
Show member pathways
12.03 MFRP MYC NTRK1 NTRK2
15 11.99 AKT1 CASP3 NGF NTRK1 NTRK2
16 11.95 AKT1 CASP3 MYC NTRK1 NTRK2 TP53
17 11.94 AKT1 MYC NF1 TP53
18 11.85 AKT1 CASP3 MYC TP53
19
Show member pathways
11.81 AKT1 CASP3 MYC NGF NTRK1 TP53
20 11.76 BACE1 ENO2 MYCN NF1 NGF NTRK1
21 11.69 AKT1 CASP3 TP53
22
Show member pathways
11.66 AKT1 CASP3 NGF TP53
23 11.64 AKT1 MYC NTRK1 TP53
24
Show member pathways
11.6 NGF NTRK1 NTRK2
25 11.51 AKT1 BACE1 CASP3 TP53
26 11.47 AKT1 CNTN6 MYC MYCN TP53
27 11.45 BACE1 NTRK1 NTRK2
28 11.41 AKT1 CASP3 MYC TP53
29 11.33 AKT1 CASP3 MYC TP53
30 11.29 AKT1 CASP3 NGF
31 10.8 CASP3 NTRK2
32
Show member pathways
10.67 NGF NTRK1 NTRK2
33 10.32 MYC MYCN

GO Terms for Peripheral Nervous System Neoplasm

Cellular components related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.1 BACE1 NF1 NGF NTRK1 NTRK2 TH

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.98 AKT1 ALK CD34 MYC TP53
2 negative regulation of gene expression GO:0010629 9.93 AKT1 CD34 MYC MYCN
3 positive regulation of apoptotic process GO:0043065 9.93 AKT1 CASP3 NF1 NGF TP53
4 cytokine-mediated signaling pathway GO:0019221 9.91 AKT1 CASP3 MYC NUMBL TP53
5 nervous system development GO:0007399 9.91 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
6 protein autophosphorylation GO:0046777 9.87 AKT1 ALK NTRK1 NTRK2
7 cellular response to organic cyclic compound GO:0071407 9.81 AKT1 CASP3 MYC
8 positive regulation of kinase activity GO:0033674 9.8 ALK NTRK1 NTRK2
9 cerebral cortex development GO:0021987 9.8 NF1 NTRK2 TH
10 neuron differentiation GO:0030182 9.8 CASP3 CNTN6 NTRK2 PHOX2B
11 cellular response to drug GO:0035690 9.79 MYC TH TP53
12 cellular response to growth factor stimulus GO:0071363 9.77 AKT1 NTRK1 TH
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 ALK NGF NTRK1 NTRK2
14 negative regulation of neuron death GO:1901215 9.75 AKT1 CD34 NTRK1
15 positive regulation of neuron apoptotic process GO:0043525 9.72 CASP3 NF1 TP53
16 response to nicotine GO:0035094 9.7 CASP3 NTRK1 TH
17 nerve growth factor signaling pathway GO:0038180 9.65 NGF NTRK1
18 cellular response to nerve growth factor stimulus GO:1990090 9.65 AKT1 NTRK1 NTRK2
19 negative regulation of astrocyte differentiation GO:0048712 9.64 MYCN NF1
20 positive regulation of mitochondrial membrane potential GO:0010918 9.62 AKT1 MYC
21 cellular response to nicotine GO:0071316 9.6 NTRK1 TH
22 mechanoreceptor differentiation GO:0042490 9.56 NTRK1 NTRK2
23 negative regulation of fibroblast proliferation GO:0048147 9.54 MYC NF1 TP53
24 response to gamma radiation GO:0010332 9.5 MYC TP53 TRIM13
25 positive regulation of gene expression GO:0010628 9.5 AKT1 CD34 MYC MYCN NGF NTRK2
26 sympathetic nervous system development GO:0048485 9.43 NF1 NTRK1 PHOX2B
27 neurotrophin signaling pathway GO:0038179 9.4 NTRK1 NTRK2
28 neurotrophin TRK receptor signaling pathway GO:0048011 9.33 CASP3 NGF NTRK1
29 negative regulation of apoptotic process GO:0043066 9.23 AKT1 ALK CASP3 MYC NGF NTRK1
30 multicellular organism development GO:0007275 10.19 AKT1 ALK NTRK1 NTRK2 NUMBL PHOX2B
31 negative regulation of cell proliferation GO:0008285 10 NF1 NGF NTRK1 PHOX2B TP53

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 MYC MYCN NFIC PHOX2B TP53
2 MAP kinase kinase kinase activity GO:0004709 9.54 ALK NTRK1 NTRK2
3 mitogen-activated protein kinase kinase binding GO:0031434 9.5 ALK NTRK1 NTRK2
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
5 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
6 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....